openPR Logo
Press release

Deadline in Lawsuit for Investors in TG Therapeutics, Inc. (NASDAQ: TGTX) on September 16, 2022 coming up

09-12-2022 11:48 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on September 16, 2022 in the lawsuit for certain investors in TG Therapeutics, Inc. (NASDAQ: TGTX).

A Deadline is coming up on September 16, 2022 in the lawsuit for certain investors in TG Therapeutics, Inc. (NASDAQ: TGTX).

A deadline is coming up on September 16, 2022 in the lawsuit filed for certain investors of TG Therapeutics, Inc. (NASDAQ: TGTX) over alleged securities laws violations by TG Therapeutics, Inc.

Investors who purchased shares of TG Therapeutics, Inc. (NASDAQ: TGTX) have certain options and there are strict and short deadlines running. Deadline: September 16, 2022. TG Therapeutics, Inc. (NASDAQ: TGTX) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of TG Therapeutics, Inc. (NASDAQ: TGTX) common shares between January 15, 2020 and May 31, 2022, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 15, 2020 and May 31, 2022, the Defendants made false and/or misleading statements and/or failed to disclose that clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of Ublituximab and Umbralisib, that accordingly, it was unlikely that the Company would be able to obtain FDA approval of the Umbralisib MZL/FL NDA, the U2 BLA, the U2 sNDA, or the Ublituximab RMS BLA in their current forms, that as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects, and that therefore, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of TG Therapeutics, Inc. (NASDAQ: TGTX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline in Lawsuit for Investors in TG Therapeutics, Inc. (NASDAQ: TGTX) on September 16, 2022 coming up here

News-ID: 2732031 • Views:

More Releases from Shareholders Foundation

Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to recover losses
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements. Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover losses
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc.. Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Malvern, PA based Ocugen, Inc., a
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) should contact the Shareholders Foundation in connection with Lawsuit
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp. Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV
Investigation announced for Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) over possible Violations of Securities Laws
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false

All 5 Releases


More Releases for Therapeutics

Digital Therapeutics Market, Digital Therapeutics Market Size, Digital Therapeut …
The global digital therapeutics market is expected to reach US$ 8,941.1 Mn by 2025 from US$ 1,993.2 Mn in 2017. The market is estimated to grow with a CAGR of 20.8% during the forecast period from 2018 to 2025. North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant
Pruritus Drug Market – Key Players are Cara Therapeutics, Enteris BioPharma, N …
The Pruritus Drug Market research report is a significant investigation of changing business sector elements, driving elements, impediments, and limitations that have been considered the most extensive impacts on market development. Adroit investigative devices, for example, Porter’s Five Forces examination, SWOT examination, and Feasibility examination study have likewise been utilized by the report to offer an exhaustive information of the market. It will go about as a key research report
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Global mRNA Cancer Vaccines and Therapeutics Market to 2025| Moderna Therapeutic …
Researchmoz added Most up-to-date research on "Global mRNA Cancer Vaccines and Therapeutics Market Size, Status and Forecast 2019-2025" to its huge collection of research reports. mRNA Cancer Vaccines and Therapeutics Market report includes (6 Year Forecast 2019-2025) includes Overview, classification, industry value, price, cost and gross profit. It also offers in-intensity insight of the mRNA Cancer Vaccines and Therapeutics industry masking all vital parameters along with, Drivers, Market Trends, Market Dynamics,
Global Pruritus Therapeutics Market Report 2019 Companies included Actavis, Trev …
Market Reports Company has recently published 7th edition of Pruritus Therapeutics Market Report which covers historic data of year 2013 to 2018 along with a forecast till year 2026. For inquiry or free sample pages email us at: sales@marketreportscompany.com The report provides a comprehensive view on the current state and future prospects of the market which analyzes different strategies for business growth. The global Pruritus Therapeutics market was valued at USD xx
MRNA Vaccines & Therapeutics Market 2019 Global Analysis By Key Players – Mode …
WiseGuyReports.Com Publish a New Market Research Report On –“ MRNA Vaccines & Therapeutics Market 2019 Global Analysis By Key Players – Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics”. Description:- The mRNA Vaccines & Therapeutics industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, mRNA Vaccines & Therapeutics market size to maintain the average annual growth rate of XXX from